Clinical Trials

Oramed recruits patients to study orally ingestible insulin capsule

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Oramed Pharmaceuticals has started recruiting patients for a new clinical trial of ORMD-0801, an orally ingestible insulin capsule, for patients with type 1 diabetes mellitus (T1DM) in Israel.

The company is also conducting ORMD-0801 US FDA trial for the treatment of type 2 diabetes. Oramed CEO Nadav Kidron said, “We are very excited to continue our development of ORMD-0801 for this high-need indication.

“We have been encouraged by our successful T1DM trials to date and we look forward to the commencement of this study.”

According to previous clinical studies, ORMD-0801 administered to T1DM patients just before a meal effectively kept their blood sugar levels stable.

Latest stories

Previous article

DiaMedica completes enrollment in DM199 single ascending dose diabetes study

Next article

The Netherlands-based company Prosena has begun the submission process for drisapersen, its treatment for Duchenne muscular dystrophy (DMD).

Related stories

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

MORE STORIES